Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

Oral verapamil lowers inflammatory markers and daily insulin needs in subjects with type 1 diabetes and helps preserve pancreatic beta cell function for at least two years. In this context, serum chromogranin A provides a promising therapy marker.

Bewaard in:

Bibliografische gegevens
Hoofdauteurs:	Guanlan Xu, Tiffany D. Grimes, Truman B. Grayson, Junqin Chen, Lance A. Thielen, Hubert M. Tse, Peng Li, Matt Kanke, Tai-Tu Lin, Athena A. Schepmoes, Adam C. Swensen, Vladislav A. Petyuk, Fernando Ovalle, Praveen Sethupathy, Wei-Jun Qian, Anath Shalev
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Nature Portfolio 2022-03-01
Reeks:	Nature Communications
Online toegang:	https://doi.org/10.1038/s41467-022-28826-3
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

Gelijkaardige items